Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Baxter
McKesson
AstraZeneca
Medtronic
Dow

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ZONEGRAN

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Zonegran

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00056576 Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy Completed Eisai Inc. Phase 3 2002-02-01 The purpose of this study is to determine whether zonisamide alone is effective as a treatment for epilepsy in newly diagnosed cases.
NCT00203450 Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial Completed Eisai Inc. Phase 4 2003-05-01 The primary objective of this study is to compare the efficacy of zonisamide (Zonegran; 100mg - 400mg/day) and placebo as an adjunctive agent on lowering weight in subjects who have a body mass index (BMI) of >25 and are on a psychotropic medication with a known side effect of weight gain.
NCT00203450 Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial Completed Tuscaloosa Research & Education Advancement Corporation Phase 4 2003-05-01 The primary objective of this study is to compare the efficacy of zonisamide (Zonegran; 100mg - 400mg/day) and placebo as an adjunctive agent on lowering weight in subjects who have a body mass index (BMI) of >25 and are on a psychotropic medication with a known side effect of weight gain.
NCT00215592 Open Label, Zonegran (Zonisamide) In Partial Onset Seizures Completed Eisai Limited Phase 4 2005-10-01 To determine the efficacy and safety of adjunctive open label Zonegran treatment in patients with refractory partial seizures.
NCT00221442 Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity Completed Eisai Inc. Phase 3 2005-08-01 The specific aim of this study is to examine the efficacy and safety of zonisamide compared with placebo in outpatients with binge eating disorder associated with obesity.
NCT00221442 Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity Completed University of Cincinnati Phase 3 2005-08-01 The specific aim of this study is to examine the efficacy and safety of zonisamide compared with placebo in outpatients with binge eating disorder associated with obesity.
NCT00221442 Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity Completed Lindner Center of HOPE Phase 3 2005-08-01 The specific aim of this study is to examine the efficacy and safety of zonisamide compared with placebo in outpatients with binge eating disorder associated with obesity.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Zonegran

Condition Name

Condition Name for Zonegran
Intervention Trials
Healthy 6
Obesity 2
Epilepsy 2
Obstructive Sleep Apnea 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Zonegran
Intervention Trials
Obesity 2
Epilepsy, Complex Partial 1
Feeding and Eating Disorders 1
Epilepsy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Zonegran

Trials by Country

Trials by Country for Zonegran
Location Trials
United States 24
Austria 2
France 1
Norway 1
Sweden 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Zonegran
Location Trials
Florida 3
West Virginia 2
Ohio 2
Alabama 2
Washington 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Zonegran

Clinical Trial Phase

Clinical Trial Phase for Zonegran
Clinical Trial Phase Trials
Phase 4 3
Phase 3 2
Phase 2 1
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Zonegran
Clinical Trial Phase Trials
Completed 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Zonegran

Sponsor Name

Sponsor Name for Zonegran
Sponsor Trials
Eisai Inc. 4
Dr. Reddy's Laboratories Limited 2
Mutual Pharmaceutical Company, Inc. 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Zonegran
Sponsor Trials
Industry 12
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Mallinckrodt
Baxter
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.